Abstract:Numerous molecular abnormalities have been described in lymphomas. They are of diagnostic and prognostic value and are taken into account for the WHO classification of these tumors. They also shed some light on the underlying molecular mechanisms involved in lymphomas. Overall, four types of molecular abnormalities are involved: mutations, translocations, amplifications and deletions of tumor suppressor genes. Several techniques are available to detect these molecular anomalies: conventional cytogenetic analysis, multicolor FISH, CGH array or gene expression profiling using DNA microarrays. In some lymphomas, genetic abnormalities are responsible for the expression of an abnormal protein (e.g. tyrosine-kinase, transcription factor) detectable by immunohistochemistry. In the present review, molecular abnormalities observed in the most frequent B, T or NK cell lymphomas are discussed. In the broad spectrum of diffuse large B-cell lymphomas microarray analysis shows mostly two subgroups of tumors, one with gene expression signature corresponding to germinal center B-cell-like (GCB: CD10+, BCL6 [B-Cell Lymphoma 6]+, centerine+, MUM1-) and a subgroup expressing an activated B-cell-like signature (ABC: CD10-, BCL6-, centerine-, MUM1+). Among other B-cell lymphomas with well characterized molecular abnormalies are follicular lymphoma (BCL2 deregulation), MALT lymphoma (Mucosa Associated Lymphoid Tissue) [API2-MALT1 (mucosa-associated-lymphoid-tissue-lymphoma-translocation-gene1) fusion protein or deregulation BCL10, MALT1, FOXP1. MALT1 transcription factors], mantle cell lymphoma (cycline D1 [CCND1] overexpression) and Burkitt lymphoma (c-Myc expression). Except for ALK (anaplastic lymphoma kinase)-positive anaplastic large cell lymphoma, well characterized molecular anomalies are rare in lymphomas developed from T or NK cells. Peripheral T cell lymphomas not otherwise specified are a heterogeneous group of tumors with frequent but not recurrent molecular abnormalities. Gene profiling analysis shows that the expression of several genes is deregulated including PDGFRA (platelet-derived growth factor receptor) gene, encoding a receptor with tyrosine kinase activity. In angio-immunoblastic T-cell lymphomas molecular abnormalities are found in follicular helper T-cell (TFH) that express some distinctive markers such as CD10, PD-1, CXCR5 and the CXCL13 chemokine. ALK-positive anaplastic large cell lymphoma is a paradigme of T-cell lymphoma since it is associated with an X-ALK oncogenic fusion protein due to a translocation involving ALK gene at 2p23. ALK tyrosine kinase activates downstream pathways (Stat3/5b, Src kinases, PLCγ, PI3 kinase) implicated in lymphomagenesis, proliferation and protection against apoptosis. Specific ALK inhibitors are currently in clinical evaluation. Lastly several lymphomas are associated with infectious agents that play a direct (EB virus, HTLV1) or indirect role (e.g. Helicobacter pylori in MALT lymphoma) in lymphomagenesis.

Lymphomas with CARMA1, BCL10, MALT1 and NF-κB signaling pathway

Molecular pathogenesis of lymphomas of mucosa-associated lymphoid tissue—from (auto)antigen driven selection to the activation of NF-κB signaling

The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling.

MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study

Clinical Features, Tumor Biology, and Prognosis Associated with MYC Rearrangement and Myc Overexpression in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-Chop

CARMA1-mediated NF-kappaB and JNK Activation in Lymphocytes.

Trimeric G Protein-Carma1 Axis Links Smoothened, the Hedgehog Receptor Transducer, to NF-κB Activation in Diffuse Large B-cell Lymphoma.

MALT lymphoma: A paradigm of NF-κB dysregulation

MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma

[Molecular abnormalities in lymphomas]

Abstract 4114: Trimeric G Protein-Carma1 Axis Links Smoothened to NF-κB Activation in Diffuse Large B-cell Lymphoma.

NF-κB Signaling Pathways Regulated by CARMA Family of Scaffold Proteins

Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level

Relationship between nuclear expression of bcl-10 and NF-κB/p65 activation in MALT lymphomas

CARMA3: A potential therapeutic target in non-cancer diseases

Potential Role of Carma1 in Cd40-Induced Splenic B Cell Proliferation and Marginal Zone B Cell Maturation

Molecular Significance of Circrnas in Malignant Lymphoproliferative Disorders: Pathogenesis and Novel Biomarkers or Therapeutic Targets

BCL10 expression and chromosomal aberration in primary cutaneous marginal zone B-cell lymphoma

A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.

Molecular Pathogenesis of B Cell Malignancy: the Role of BCL-6

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma